VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Moves Forward in Developing As-Needed Treatment for Social Anxiety Disorder
Company signs a worldwide licensing agreement with Pherin Pharmaceuticals for the development and commercialization of a Phase 3-ready CNS drug candidate for as-needed treatment of social anxiety disorder Untreated social anxiety disorder has a significant impact on a person’s overall quality of life Clinical studies support the potential of PH94B to be a superior treatment alternative for SAD due to the demonstrated rapid onset of efficacy, route of administration, as-needed dosing convenience and excellent safety profile VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and…